Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Terazosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.96 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.96 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | GLA | P06280 | 4/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.98 |
| ▸ | HPGD | P15428 | 4/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.96 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.96 |
| ▸ | DRD1 | P21728 | 2/20 | 0.96 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.96 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.96 |
| ▸ | TP53 | P04637 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terazosin SCHEMBL1172921 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL8540346 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL5421873 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL29361818 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL5918282 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL3221979 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL9079964 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL9195360 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL9053035 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL41544 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375376-A1 | STABLE ORAL LIQUID COMPOSITION OF TERAZOSIN | Novitium Pharma LLC (US) | 2025-12-11 | — | — | US | disclosed |
| US-12427108-B2 | Stable oral liquid composition of terazosin | Novitium Pharma LLC (US) | 2025-09-30 | — | — | US | disclosed |
| US-20220047508-A1 | STABLE ORAL LIQUID COMPOSITION OF TERAZOSIN | Novitium Pharma LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11224572-B1 | Stable oral liquid composition of terazosin | Novitium Pharma LLC (US) | 2022-01-18 | — | — | US | disclosed |
| EP-3150205-B1 | TRANSDERMAL PREPARATION | TEIKOKU SEIYAKU KK (JP) | 2021-02-17 | — | — | EP | disclosed |
| US-10137098-B2 | Transdermal preparation | TEIKOKU SEIYAKU CO., LTD. (JP) | 2018-11-27 | — | — | US | disclosed |
| EP-3150205-A1 | TRANSDERMAL PREPARATION | Teikoku Seiyaku Co., Ltd. (JP) | 2017-04-05 | — | — | EP | disclosed |
| US-20170079940-A1 | TRANSDERMAL PREPARATION | TEIKOKU SEIYAKU CO., LTD. (JP) | 2017-03-23 | — | — | US | disclosed |
| EP-3023109-A1 | ORALLY DISINTEGRATING TABLET | Sanwa Kagaku Kenkyusho Co., Ltd (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-20160136091-A1 | Orally Disintegrating Tablet | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2016-05-19 | — | — | US | disclosed |
| CN-105377303-A | Orally disintegrating tablet | SANWA KAGAKU KENKYUSHO CO | 2016-03-02 | — | — | CN | disclosed |
| EP-2924037-A1 | QUINAZOLINE DERIVATE AND USE THEREOF AS APOPTOSIS INHIBITOR | Linx Pharmaceutical Co., Ltd. (CN) | 2015-09-30 | — | — | EP | disclosed |
| EP-0770612-B1 | Terazosin crystalline polymorph and pharmaceutical compositions thereof | INVAMED INC (US) | 1998-08-26 | — | — | EP | disclosed |
| EP-0770612-A1 | Terazosin crystalline polymorph and pharmaceutical compositions thereof | Invamed Inc. (US) | 1997-05-02 | — | — | EP | disclosed |
| US-5587377-A | HYPOTENSIVE AGENT | INVAMED, INC. (US) | 1996-12-24 | — | — | US | disclosed |